Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Erin M. Bange(Memorial Sloan Kettering Cancer Center), Ronac Mamtani(Hospital of the University of Pennsylvania), Abigail Doucette(University of Pennsylvania), Bethany I. Mooney(University of Pennsylvania), Ben Boursi(Tel Aviv University), Peter Gabriel(University of Pennsylvania), Andrzej P. Wojcieszynski(University of Pennsylvania), Robin Wang(University of Pennsylvania), Kim A. Reiss(University of Pennsylvania), Florence Porterfield(University of Pennsylvania), James J Harrigan(University of Pennsylvania)
Cited by 64
Related Papers
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|519
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
|JAMA Oncology|2019|289
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>
|Journal of Clinical Oncology|2021|238
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
|British Journal of Cancer|2019|206